Back to Health

What Is Rilpivirine and What Is It For?

What Is Rilpivirine and What Is It For?
Bareback Guide 11 March 2026

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor known for being well tolerated and for two conditions that govern how it can be used.

What kind of drug is it?

A non-nucleoside, which targets the same enzyme as the nucleoside analogues by a different route. Rather than posing as a DNA building block, it disables the enzyme directly.

How does it work?

HIV must convert its RNA genome into DNA using reverse transcriptase. Rilpivirine binds to a pocket on the enzyme and changes its shape so the conversion can no longer be performed.

What are the two conditions?

It must be taken with a substantial meal, because absorption depends on it. And it is not suitable for people starting treatment with a very high viral load or a low CD4 count, because effectiveness falls in that group.

Why does the viral load matter?

Because trials found higher rates of virological failure among participants starting with more than 100,000 copies. That finding directly shaped the licensing, and it is why rilpivirine is more often a switch option than a starting one.

What is it used for?

HIV treatment as part of a combination, usually for people already suppressed and switching. It is also half of the long-acting injectable regimen given with cabotegravir every two months.

Why is it used in the injectable regimen?

Because it could be formulated as a long-acting injectable suspension and because it pairs with cabotegravir to provide two active drugs. Injectable treatment requires two, and these are the two available.

Does it need a booster?

No. It maintains adequate levels for a full day on its own, which avoids the interaction problems that boosters create.

What is its main advantage?

Tolerability. Compared with efavirenz, the other widely used non-nucleoside of its era, it produces far fewer neuropsychiatric effects and has a better lipid profile.

What is its main drawback?

The food requirement, which is genuinely strict rather than advisory, and the interaction with anything that reduces stomach acid.

What is its resistance barrier?

Moderate, as with the class generally. Missed doses carry more risk than with integrase inhibitors, and resistance to it overlaps with resistance to other non-nucleosides.

Does it cover hepatitis B?

No. Regimens containing it may, through a lamivudine or tenofovir component. The two-drug combination with dolutegravir does not, which matters for anyone with chronic hepatitis B.

How quickly does it work?

Viral load falls within the first weeks, with suppression usually established within one to six months. Where it is used as a switch for someone already suppressed, suppression is maintained rather than achieved.

How long has it been available?

Since the early 2010s in tablet form, with the long-acting injectable arriving around a decade later. There is a solid body of experience with both.

Where does it sit against the alternatives?

Behind integrase inhibitors on resistance barrier and convenience, ahead of efavirenz on tolerability. Its unique position is as half of the only injectable treatment regimen currently available.